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Objective: To increase understanding of HLV infection risk among patients
with severe mental illness, the study sought to identify predictors of injection
drug use among patients who did not have a primary substance use disorder.
Methods; A total of 192 patients recruited from inpatient and outpatient pub-
lic psychiatric facilities were interviewed by trained mental health profes-
sionals using the Structured Clinical Interview for DSM-III-R (SCID), the
Positive and Negative Syndrome Scale, and the Parenteral Drug Use High-
Risk Questionnaire. Results: Sixty percent of the sample met SCID criteria
for lifetime substance abuse or dependence. Although only two patients re-
ported drug injection in the past six months, 38 (20 percent) had injected
drugs since 1978, the year that HIV began to spread in the U.S. A lifetime di-
agnosis of opioid abuse or dependence was a strong predictor of drug injec-
lion, but only 11 of the 38 patients with a recent history of injection drug use
had either ofthese diagnoses. The likelihood ofinjecting drugs was four times
greater among patients with a history of intranasal substance use compared
with those without such use, three and a half times greater among African-
American patients than among non-African-Americans, and five times
greater among patients aged 36 or older compared with younger patients.
Conclusions: In assessing HIV risk among patients with severe mental illness,
it may be more important to identify the route of drug administration than
the specific substances used because of the strong association between in-
tranasal drug use and history of injection. (Psychiatric Services 47:181-185,
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D rug injection is a well-known
vector for the transmission of
HIV (1). Among diverse
groups of psychiatric patients in New
York City, HIV seropositivity has
been reported to range from 4 per-
cent to 22.9 percent (2-9). Injection
drug use is a consistent predictor of
HIV infection in psychiatric patients
(2-4,6-9). Detection ofa history of in-
jection drug use is often inadequate
in psychiatric settings (3,10,11); how-
ever, in studies in which clinicians
can document such use, it is associat-
ed with a two- to ten-fold increase in
a persons likelihood of testing HIV
positive (2-4,6,8,9). Identification of a
history of injection drug use often oc-
curs after HIV diagnosis (12).
Most studies of HIV risk behavior
among people with severe mental ill-
ness focus on unsafe sexual activity,
but injection drug use may be an
equally important mode ofHIV trans-
mission in this population. The small
number of studies of this risk behav-
ior have simply reported rates of re-
cent injection drug use-i percent to
2 percent (13,14)-or use in the
past-4 percent to 20 percent
(5,13-17). Only one study examined
the relationship of injection drug use
and age, gender, ethnicity, and psy-
chiatnic diagnosis, and it found no as-
sociation (13). Identification of factors
associated with use of injection drugs
would make HIV risk screening and
preventive interventions more effec-
tive.
In this study, we attempted to go
beyond simply reporting rates and
identified sociodemographic and
clinical determinants of illicit-drug
injection among psychiatric inpa-
tients and outpatients. We examined
the relationship between injection
drug use and psychiatric diagnosis,
chronicity of psychiatric illness, level
of functioning, and psychiatric symp-
toms. We used standardized assess-
ment interviews, an approach widely
recommended but seldom taken in
research on comorbidity of substance
use and psychiatric disorders (18-20).
Methods
Sample and data collection
Clinicians at four sites serving people
with severe and persistent mental ill-
ness in New York City were asked to
refer to the study all patients seen be-
tween March 1990 and May 1991
who were between the ages of 18 and
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59 and had any psychiatric diagnosis
and whom they judged capable of
consenting to give a face-to-face re-
search interview. Patients with a pri-
mary diagnosis of substance abuse or
dependence were excluded from the
four treatment programs. The sites
were a day treatment program and
three inpatient units: acute care, spe-
cialized homeless, and community
preparation units. Inpatients either
were recently admitted or had oppor-
tunities for drug use during furloughs
off hospital grounds. Study proce-
dunes have been described in detail
elsewhere (13,21).
Sociodemographic data were oh-
tamed from interviews with patients
and corroborated by patient records.
A psychiatric diagnosis was made
based on the Structured Clinical In-
terview for DSM-III-R (SCID) (22).
The Global Assessment of Function-
ing scale (GAF), which is part of the
SCID, was used to rate each patient’s
overall level of functioning on a scale
from 0, indicating persistent danger
to self or others, to 90, indicating a
lack of or minimal symptoms. Assess-
ment of current psychopathology was
supplemented by the Positive and
Negative Syndrome Scale (PANSS)
(23), which rates symptoms on a scale
from 1, no symptoms, to 7, extreme
symptoms.
Information about drug injection
and intranasal drug use was elicited
using a modified Parenteral Drug Use
High-Risk Questionnaire (24), which
covers the previous six months and al-
so covers the years between 1978 and
six months before the interview. The
year 1978 has been identified as the
point at which HIV began to spread
in the United States (25) and among
drug injectors in New York City (26).
Data analysis
We sought to develop a prediction
model using logistic regression analy-
sis, which requires dichotomous cate-
gonical vanial)les . Continuous van-
ables (age, number of previous hospi-
talizations, GAF scores, and PANSS
scores) were dichotomized above and
below median values. Ethnicity was
dichotomized as African American
versus non-African-American because
previous studies at the same sites
(3,27) found disproportionately ele-
vated HIV infection rates among AT-
rican-American patients. Lifetime alco-
hol abuse and dependence was dicho-
tomized as meeting or not meeting
SCID criteria.
Chi square tests were used to ex-
amine differences between patients
with and without a history of injection
drug use. Unadjusted and adjusted
odds ratios were used to estimate rel-
ative risk of injection drug use. When
unadjusted odds ratios showed signif-
icant associations between an inde-
pendent variable and drug injection,
adjusted odds ratios were derived
from the regression analysis to esti-
mate the relative risk of drug injec-
tion for each factor (28), controlling
for the effects of all others entered
stepwise into the equation.
Results
Of the 264 patients referred to the
study, 61 did not consent to partici-
pate, resulting in an overall participa-
tion rate of 77 percent. Three patients
dropped out of the study after con-
senting, and assessments were not
completed for eight other patients due
to transfer or discharge. The final sam-
ple consisted of 192 patients for whom
all measures were completed. Patients
who participated in the study did not
differ from nonparticipants in age,
gender, number of previous psychi-
atric hospitalizations, or documented
history of substance abuse treatment.
Participant characteristics
Table 1 shows sociodemographic and
clinical characteristics of the 192 par-
ticipants. The sample was ethnically
diverse. The median age was 36.
About one-third of the participants
were female. Nearly every patient
had a psychotic disorder. A median of
four previous psychiatric hospitaliza-
tions and a median GAF score of 40
indicated that patients had severe and
chronic psychiatric illnesses.
Table 2 presents information about
participants’ substance use disorders.
Twenty-three patients (12 percent)
met criteria for current substance
abuse or dependence: one patient
had an alcohol-related disorder, 20
had disorders related to both alcohol
and other substances, and two had
substance-related disorders not in-
volving alcohol. All patients who met
criteria for current abuse or depen-
dence also met criteria for past abuse
or dependence.
A total of 116 patients (60 percent)
met criteria for lifetime substance
abuse or dependence-27 (14 per-
cent) for alcohol alone, 56 (29 per-
cent) for alcohol and other sub-
stances, and 33 (17 percent) for sub-
stances other than alcohol.
Drug Injection
Thirty-eight patients (20 percent) re-
ported injection of illicit drugs since
1978. Current use of injection drugs
(that is, during the previous six
months) was reported by two patients
(1 percent). Thirty-seven patients (19
percent) reported that they had used
injection drugs since 1978 but not in
the previous six months; one ofthe 37
also reported current injection.
Unadjusted and adjusted odds ra-
tios for injection drug use are pre-
sented for sociodemographic and
clinical characteristics in Table 1 and
for substance use histories in Table 2.
Using unadjusted odds ratios as an es-
timate of relative risk, several vari-
ables were found to be significantly
associated with drug injection since
1978. They were age over 36 years;
African-American ethnicity; more
than four previous psychiatric hospi-
talizations; a PANSS positive symp-
tom score greater than 12; a lifetime
diagnosis of alcohol, cocaine, or opi-
oid abuse or dependence; and a histo-
ry of intranasal drug use.
Adjusted odds ratios, which simul-
taneously control for the effects of all
significant univaniate associations,
showed that patients over age 36
were five times more likely to have
injected drugs since 1978 compared
with those who were age 36 or
younger. African-American patients
were nearly three and a half times as
likely as non-African-American pa-
tients to have injected drugs since
1978. Patients who met SCID criteria
for a diagnosis of opioid abuse or de-
pendence were more than seven
times as likely as those without the di-
agnosis to have an injection history.
Patients who reported a history of in-
tranasal drug use were nearly four
times as likely as those who did not
report this history to have injected
drugs since 1978.
Table 1
Sociodemographic and clinical characteristics and illicit-drug injection since 1978
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ry. Sniffing drugs was a more power-
ful predictor of injection drug use
than a history of alcohol or cocaine
abuse or dependence.
Only 8 percent of patients met
SCID criteria for a lifetime diagnosis
of opioid abuse or dependence. Not
surprisingly, these patients were sev-
en times more likely to have an injec-
tion history than those who did not
meet the diagnostic criteria. Howev-
er, only 29 percent of injectors met
criteria for a diagnosis ofopioid abuse
or dependence at any time in their
lives. Eleven of 14 patients (79 per-
cent) with this diagnosis reported a
.29 1.50 0.70-3.19 history of injection drug use; of the
remaining three opioid abusers with-
out an injection history, two reported
.02 2.28 1.10-4.70 intranasal use, and for one the route
of administration was unknown. In
.89 1.03 0.41-2.56 the absence of a lifetime diagnosis of
comorbid opioid abuse or depen-
dence, the route of drug administra-
tion appears to be a better predictor
of injection drug use in psychiatric
patients than having a nonopioid sub-
stance use disorder.
Drug injection was more prevalent
among African-American patients
.13 1.79 0.83-3.87 than others. In seroprevalence stud-
ies among new admissions to two
public psychiatric hospitals (3), we
found that African-American patients
were almost six times more likely to
.18 1.65 0.79-3.42 be HIV positive than non-African-
American patients. That African-
.01 2.48 1.19-5.16 American patients in the study re-
ported here were three and a half
times more likely to have injected
.12 1.78 0.86-3.70 drugs since 1978may partly explain
the earlier finding. Although the so-
cioeconomic status of the patients in
this study varied little, other contex-
tual determinants, including geogra-
phy (29) and degree of drug depen-
dence (30), may explain this finding.
The relatively low rate of injection
drug use reported by Latino patients
in this study is consistent with find-
ings from the National Household
Survey on Drug Abuse (31). Injection
drug use may vary by ethnic group
due to differences that were not mea-
sured in this study, including degree
ofacculturation (32) or cultural differ-
ences in reporting this behavior.
Patients over age 36 were five times
more likely than younger patients to









1 Value is for chi square test,
 dfl; adjusted odds ratio5.26, 95% confidence intervall.72-16.04, p.004
.3  df= 1 adjusted odds ratio3.40, 95% confidence interval 1.23-9.32, p,02
4 X2=658 df2; odds ratios for ethnicity compare African-American patients with all other pa-
tients.
5 X25.24 df= 1
6 Odds ratios for diagnosis compare affective disorders with all other disorders.
7 N = 189 due to missing data
5X26.09, df=1
9 N=191 due to missing data
Discussion
Predictors ofdrug injection
One in five patients we interviewed
reported having injected drugs since
1978, and we identified several pre-
dictors of injection.
This study is the first to show that
intranasal drug use predicts injection
drug use in this population. Almost
half (44 percent) of all patients had a
history of intranasal drug use, and
these patients were nearly four times
more likely to have used injection
drugs than patients without this histo-





18 to 36 years


































29 or higher 86
Positive symptoms8
12 or lower 105































Substance use histories and illicit-drug injection since 1978 among 192 psychiatric










13 6.8 5 38.5
9 4.7 2 22.2
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1 Value is for ciii square test.
2 2=23 df= 1
3 x=6.#{176}7df=1
4X24’2. df=1
5 x2=3l.83’ dfl; adjusted odds ratio7.10, 95% confidence intervall.40-35.98, p.O2
6  df= 1; adjusted odds ratio3.84, 95% confidence interval 1.34-10.99, p.Ol

















injection drugs typically begins by
the mid-twenties (33), so younger pa-
tients in this study would not have
reached the age at which injecting
typically begins. The lower preva-
lence of injection drug use among
younger patients may also reflect the
relatively recent appearance of crack,
a smokable form of cocaine, and its
use as an alternative to injectable
drugs. The increasing availability of
HIV risk and prevention information
in the community may also partly ac-
count for the lower prevalence.
Only two patients reported recent
injection. In light of the much higher
rate of past injection in the sample, it
appears that injection drug use may
be an intermittent behavior. As many
as 70 percent ofpast injectors may re-
sume injection even after stopping for
a year or more (34). Therefore, pa-
tients with a history of injection or in-
tranasal drug use must be considered
at risk of future injection, and inter-
ventions should be targeted at pre-
venting this behavior.
We did not inquire about sharing
contaminated injection equipment, the
date when patients began injecting or
sniffing drugs, or how use of particular
substances related to equipment shar-
ing or to age at first use. We do not
know whether or when patients who
sniff drugs progress or revert to inject-
ing. Longitudinal study of injection
drug use in this population is critical.
Despite these limitations, our study
found that inquiring about the route of
drug administration is a crucial step in
taking an HIV-risk history and may be
more important as a predictor of HIV
exposure risk than asking patients
which drugs they use.
Despite the exclusion of patients
with primary diagnoses of substance
use disorders from admission to the
study sites, 12 percent of the study
participants met criteria for current
substance abuse or dependence. This
finding indicates that the absence of a
current comonbid substance-related
diagnosis is an unreliable criterion for
ruling out risk of HIV infection from
drug injection. In a large prospective
study ofdrug users who had never in-
jected, 30 percent reported initiating
injection drug use within five years
after the study began (34).
Use of the SCID to assess patients’
clinical status may have underesti-
mated the prevalence of substance
use disorders. To avoid false positives,
respondents to the SCID must pro-
vide clear examples of symptoms, ei-
then verbally or by their behavior dun-
ing the interview (35). In psychiatric
patients, rates of comorbid substance
use disorders ranging from 20 per-
cent to 75 percent have been report-
ed (18-20,36,37), which are substan-
tially higher than rates ofdual diagno-
sis in the general population found by
the Epidemiologic Catchment Area
study (38) and the National Comor-
bidity Survey (39).
The specific psychiatric diagnosis,
which was established by a standard-
ized assessment instrument, did not
differentiate patients who had inject-
ed illicit drugs from those who had
not. Measures of severity of illness,
psychiatric symptoms, and level of
functioning also failed to predict in-
jection drug use. Therefore, clinical
characteristics do not appear to be re-
liable predictors of drug injection in
people with severe mental illness.
Conclusions
We sought to identify predictors of ii-
licit-drug injection among a group of
severely and chronically ill psychiatric
patients in New York City. Although il-
licit substances are presumably more
widely available in New York City than
in many other regions of the United
States, high rates of injection drug use
have been reported elsewhere
(29,40-42). However, our results may
be specific to urban areas, where many
psychiatric patients live (16).
We found that a history of intranasal
drug use was the best behavioral pre-
dictor of drug injection. Even when
public mental health programs screen
out by administrative mandate pa-
tients with primary diagnoses of sub-
stance use disorders, drug injection
constitutes a prominent HIV risk be-
havior among the patients they treat. A
critical need exists for implementation
of realistic and appropriate substance
abuse assessment, treatment, and pre-
ventive interventions in all programs
for people with severe psychiatric dis-
orders. Implementing such efforts
would be an important step toward
primary prevention of HIV infection
in this population. #{149}
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